Home » Hydra Lands Potential $195M Deal With Pfizer on Pain Drugs
Hydra Lands Potential $195M Deal With Pfizer on Pain Drugs
Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million.
BioWorld Online
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May